chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I have dry skin but it has never caused any problem. I have always used products to motorize my skin with no issues. After the 3rd shot, I started itching everywhere like my trunk and head. I have also developed an itch wherever spandex/jean material meet my skin. I had itching anywhere my skin came in contact with spandex/elastic like underwear and my bra. I also had generalized itching on my back. I was having a hard time so I went to see the doctor. The doctor had no indications of anything. Please not at the time I didn't change any of my daily routine everything was the same (products, soaps, deodorant etc.) The doctor did see two tiny spots that she identified as eczema, pinpoint in size and very small. One of the dots didn't even touch any spandex/elastic but was still very irritated. One dot was on my abdomen and the other was on my hip. Prescribed triamcinolone acetonide cream 0.1%. When I put the cream on the spot, they eventually went away but new spot did pop up that also responded well to the cream. I still have the pinpoint dot that have infrequently occur on my trunk. I have switched to all cotton shirts, which is hard to find, I have bought new underpants with limited spandex which has helped. Cetaphil, Aquaphor, Vanicream, T-gel shampoo. The doctor stated that maybe there was something that happened with the immune system to simulate some kind of reaction which caused the rash and itchiness.
minor heart attack; stent put in; A spontaneous report was received from a consumer who was also a 75 year old female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced a minor heart attack / myocardial infarction and stent was put in / stent placement.  The patient's medical history was not provided. No relevant concomitant medications were reported.    On 25-Jan-2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 in the left arm for prophylaxis of COVID-19 infection.  On 13-Feb-2021, the patient experienced a minor heart attack and had a  stent placement.    Action taken with mRNA-1273 in response to the event was not reported.   The outcome of the events, minor heart attack and stent was put in, was not provided.; Reporter's Comments: Very limited information regarding the events has been provided at this time.  Further information has been requested.
Itching, red and swollen rash-like area on the left arm where injection site was. Was fine and nothing there until a few days ago from today's date of 3/5/2021
16-hour post vaccine fever of 102.4F. Fever down to 100.7F as the lowest 24 hours later. Joint pain in neck, shoulders, knees, and ankles. Muscle pins and weakness in neck, shoulders, upper arms, abdomen, and thighs. 48-hours post vaccine temperature in the 99F range with continued joint and muscle pain and weakness. Sore throat a new symptom 48 hours later.
Patient presented with abdominal pain. She was diagnosed with acute duodenitis of unknown cause. She may have inflammation or maybe even some ulcer disease there, but she quickly tolerated her diet here with minimal pain and was discharged home with follow up this Wednesday to get her second round of chemotherapy. ED visit to hospital admission within 6 weeks of receiving the COVID vaccine.
Dizziness; Super weak; Heart palpitation; Burning sensation in her lungs; Super cold; Pain in left arm; Pain in breast; Chills; Headache; This spontaneous case was reported by a consumer and describes the occurrence of FEELING COLD (Super cold) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in April 2020.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jan-2021, the patient experienced FEELING COLD (Super cold). At the time of the report, FEELING COLD (Super cold) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
6/13/20- MOC brought in pt in clinic  c/o fever, rash a few days post vaccination. Rash started on neck and spread down to body per mom. Ibuprofen was prescribed for pain/fever. Triple antibiotic was also recommended for lesion. Pt was followed up on 6/15/20 via Telehealth. Provider prescribed Benadryl and Calamine lotion. Pt has another follow appt scheduled on 6/22/20.
having problems; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (having problems) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (having problems). At the time of the report, VACCINATION COMPLICATION (having problems) outcome was unknown.            Company Comment : This case concerns a patient with unknown age and sex who experienced non-serious , unexpected event of Vaccination complication which occurred on an unknown date after vaccination with the 3rd dose ( booster dose) of mRNA-1273 vaccine ( Moderna Covid 19 vaccine). The re-challenge for this case is not applicable since the outcom e of the event is unknown and also the event happened after the 3rd dose and no additional doses will be given. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.  No concomitant medications was reported. No treatment drug details was reported.; Sender's Comments: This case concerns a patient with unknown age and sex who experienced non-serious , unexpected event of Vaccination complication which occurred on an unknown date after vaccination with the 3rd dose ( booster dose) of mRNA-1273 vaccine ( Moderna Covid 19 vaccine). The re-challenge for this case is not applicable since the outcom e of the event is unknown and also the event happened after the 3rd dose and no additional doses will be given. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.
Initial unsolicited report received from the consumer (patient's wife). This case involves a 28-years-old male patient who was vaccinated with a dose of SMALLPOX VACCINE (SMALLPOX) in left deltoid and the dose of ANTHRAX VACCINE (ANTHRAX) in right deltoid (batch number, expiry date, dose in series, dose and route of administration was not reported) on 11 February 2017. Illness at the time of vaccination and other medical history was none. Concomitant medications were not reported. On 17 February 2017, six days following the vaccination, the patient had experienced pain and swelling at the site of the smallpox vaccination along with a fever of 100F, chills, muscle and joint aches. Other relevant laboratory data was not reported. The patient was self-medicating with Ibuprophen as corrective treatment. The outcome of the event was not reported. List of documents held by sender: none.
Child into health dept. 11-12-02 with grandma, rash crusted over on left thigh and a few on both arms; Also knot with bruise noted on lower left leg. Encouraged Grandma to follow-up with pediatrician.
Fever; Not feeling well; This is a spontaneous report from a contactable consumer or other non hcp. This consumer (patient) reported that a patient of unspecified age and gender received bnt162b2 (BNT162B2, Batch/Lot number: EW0183), via an unspecified route of administration on 04Jun2021 as 2nd dose, single dose  for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unknown date in Jun2021, the patient experienced fever and not feeling well. It was reported that consumer stated "I actually got my second Pfizer dose yesterday (04Jun2021) and I was having some fever so, I wanted to know can I take Tylenol or Advil or there was any preferred medicine which I need to take to reduce the fever." The outcome of both events was unknown.  No follow-up attempts are possible. No further information is expected.
This spontaneous report as received from a nurse refers to 5 patients of unknown age. No concomitants were reported. On 20-MAY-2014, the patients were vaccinated with ROTATEQ inj, lot J015062, expiration date 13-OCT-2015 (dose, frequency, route of administration and indication were not provided) that was exposed to 8.8C for 10 days. No adverse effects reported. No product quality complaint (PQC) was involved. The outcome of events was unknown. On 02-JUN-2014 a phone call was placed to reporter. The receptionist stated they do not have any one by that name employed at this facility. No further information is available at this time. This report is linked to 1405USA013915 and 1405USA013916, 1406USA004906, 1406USA004908, 1406USA004909, 1406USA004913, 1406USA004914, 1406USA004915, 1406USA004863, 1406USA004874, 1406USA004881, 1406USA004891, 1406USA004897, 1406USA004900, 1406USA004901, 1406USA004814, 1406USA004830, 1406USA004831, 1406USA004832, 1406USA004833, 1406USA004835, 1406USA004837 by the same reporter link. Additional information is not expected.
Burning and swelling of tongue with metallic taste, hives body wide, chest congestion, runny nose, stiff neck, no normal bowel movement for 11 days.
This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a male patient who received SHINGRIX for prophylaxis. In May 2018, the patient received the 1st dose of SHINGRIX. In August 2018, 91 days after receiving SHINGRIX, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown. The reporter considered the shingles to be unrelated to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The reporter did not attribute receipt of SHINGRIX with the development of shingles. The reporter did not obtain any information other than patient gender and the dose was received sometime in May 2018 and patient was with shingles at the time of reporting (approximately 3 months latency).
there is currently mild pain associated with moving of the left arm; swelling,Swelling of left arm; Injection site warm to touch, warmness to touch; itchiness; Pain at injection site; a red rash was noted at the injection site; Rash at injection site; Chest pain; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (Chest pain), PRURITUS (itchiness), PAIN IN EXTREMITY (there is currently mild pain associated with moving of the left arm), PERIPHERAL SWELLING (swelling,Swelling of left arm) and VACCINATION SITE WARMTH (Injection site warm to touch, warmness to touch) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Apr-2021, the patient experienced CHEST PAIN (Chest pain). On 29-Apr-2021, the patient experienced PRURITUS (itchiness), PERIPHERAL SWELLING (swelling,Swelling of left arm), VACCINATION SITE WARMTH (Injection site warm to touch, warmness to touch), VACCINATION SITE PAIN (Pain at injection site), VACCINATION SITE ERYTHEMA (a red rash was noted at the injection site) and VACCINATION SITE RASH (Rash at injection site). On an unknown date, the patient experienced PAIN IN EXTREMITY (there is currently mild pain associated with moving of the left arm). On 21-Apr-2021, CHEST PAIN (Chest pain) had resolved. At the time of the report, PRURITUS (itchiness), PERIPHERAL SWELLING (swelling,Swelling of left arm), VACCINATION SITE WARMTH (Injection site warm to touch, warmness to touch), VACCINATION SITE PAIN (Pain at injection site), VACCINATION SITE ERYTHEMA (a red rash was noted at the injection site) and VACCINATION SITE RASH (Rash at injection site) had not resolved and PAIN IN EXTREMITY (there is currently mild pain associated with moving of the left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Treatment details included that the patient was advised to remove their mask, deep breath and slowly the pain went away and Cortisol Cream was used by the patient at the injection site.
Woke up at 07:20 which chest tightness/pain  and uncontrollable shaking.  Temperature was 102 with hospital grade temporal thermometer.  Pulse rate of 140 and POX of 96.  At 07:23 took 650mg Tylenol and 50mg  oral diphenhydramine with 16 oz water.    Chest tightness subsided around 10 minute mark and shaking stopped after one hour.  Sleep from 10:00-16:00.  Woke up with a headache and mental confusion.
NO ADVERSE EVENTS OCCURRED. PATIENT RECEIVED A BOOSTER DOSE OF THE PFIZER VACCINE AT AN OFF-SITE CLINIC. PATIENT WAS UNDER THE AGE OF 18 AT THE TIME OF ADMINISTRATION.
pt recv vax 1600 8APR;hives on rt thigh since 0800 9APR96 DPH po for treatment;
patient had tinder arm starting the same day when he got the vaccine. net day pain in shoulder arms and hands. then he was diagnosed with rheumatoid Arthritis, been on steroid course to help with the pain.
Woke up this morning with dizziness, weakness, headache, aches. Unable to come to work.
Patient tested Covid + 6/20/22 and again 7/3/22. Admitted to Hospital
At approximately 5:45 pm, staff found patient in an active seizure. His vitals were  BP 163/73, SP02  98% Temp 96.9 and RR 16. Patient was given keppra as ordered and noted to have L sided weakness  to arms and legs which resolved. Later that evening Patient then had an elevated temperature and was given 1 dose of Apap. The patient continued to have elevated temperature with shivering, increasing pain, lethargy and inability to swallow. His temperature was 102.8.
Narrative:  COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 08/01 pt cc: cough, chills, myalgias, upper back pain exposure: unknown 08/07 COVID swab, result: detected 08/07 admitted to ED dx: COVID-19 positive, Acute viral bronchitis, Hypoxemia transfer to in-patient medicine 08/07 CXR impression: 1. Mild bilateral pulmonary opacities, possible pneumonia and/or edema. 2. Clinical correlation and follow-up are recommended. 08/08 ESR 54 08/08 FIBRINOGEN 347 08/08 DDIMER 1.63 8/12 SARS-COV-2 LINEAGE result: AY.4 08/12 SARS-COV-2 CLADE results: 21A Delta 08/12 ESR 54 08/12 DDIMER 3.0 08/16 ESR result: 22 08/15 CTA PE impression: No evidence of pulmonary embolism. 2. Cardiomegaly with left ventricular dilatation 3. Underlying emphysematous change with diffuse bilateral interstitial changes favoring edema over infection. There are a few somewhat rounded more focal airspace densities present in the posterior right upper lobe and the right lung base which could represent airspace edema, superimposed pneumonia or lung nodules. 4. Trace bilateral pleural effusions 08/17 CXR impression: Interval worsening of mixed interstitial and airspace opacities. 08/19 procalcitonin 0.18 8/19 pt 13.0, inr 1.16, fibrogen 284, ddimer 7.19 08/19 BNP result: 450.6 08/19 MRSA result: not detected 08/19 CXR impression: No significant interval change. 08/22 pt deceased
Patient was vaccinated with expired Moderna Toddler Vaccine. Parent brought back to repeat the dose
second dose is pfizer; This spontaneous case was reported by an other health care professional and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (second dose is Pfizer) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 052E21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 08-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Sep-2021, the patient started TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) at an unspecified dose. On 29-Sep-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (second dose is pfizer). On 29-Sep-2021, INTERCHANGE OF VACCINE PRODUCTS (second dose is pfizer) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided. Treatment information was not provided.  On 29-Sep-2021, the patient received second dose of PFIZER  COVID-19 VACCINE in (lot 30155BA) in left deltoid.   Most recent FOLLOW-UP information incorporated above includes: On 01-Oct-2021: Follow-up received on 01-OCT-2021 Updated reporters more details and Vaccine route of administration.
Patient came in to receive the covid bivalent vaccine and she got the non-bivalent covid 19 vaccine instead.
Information has been received from a registered nurse concerning a patient who on 03-Sep-2003 was vaccinated SC with a dose of varicella virus vaccine live (lot unknown). On 10-Sep-2003 the nurse received a call from the patient's mother reporting that the child had a scab that was crusted over on the forehead. The nurse indicated that she was unsure if this was a breakthrough event. Unspecified medical attention was sought. A product quality complaint was not involved. No other information was available. Follow-up information indicated that the scab was "not related" to varicella virus vaccine live. No further information is expected.
Patient developed a diffuse erythematous rash around injection site of left arm which spread over the course of 2-3 days and remained persistent over the course of 9 days when the pt was evaluated again in the office. There was no sign of infection, area was not indurated or especially painful to touch or warm to touch. Treatment was recommended with topical ice and Benadryl and ibuprofen/Tylenol PRN. Symptoms included fatigue and red rash.
The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022; The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022) and PRODUCT STORAGE ERROR (The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022) and PRODUCT STORAGE ERROR (The vaccine was refrigerated on 25-Mar-2022, it got expired on 01-Dec-2021 but was administered on 04-Apr-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not reported.  Patient received the second booster dose.  The vaccine was expired on 01-Dec-2021, but was refrigerated on 25-Mar-2022 and was latter administered on 04-Apr-2022.  Vial did not undergo any temperature excursions.  Treatment medication was not reported.
Felt like a truck ran over her; Was very sore and achy all over; Severe hot flashes; sweating all over body; Weak; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Felt like a truck ran over her), MYALGIA (Was very sore and achy all over), HOT FLUSH (Severe hot flashes), HYPERHIDROSIS (sweating all over body) and ASTHENIA (Weak) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     The patient's past medical history included Atrial fibrillation. Concomitant products included RIVAROXABAN (XARELTO) for Anticoagulant therapy, FUROSEMIDE for Fluid and electrolyte imbalance, ATENOLOL for Heart rate.    On 06-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Feb-2021, the patient experienced PAIN (Felt like a truck ran over her), MYALGIA (Was very sore and achy all over), HOT FLUSH (Severe hot flashes), HYPERHIDROSIS (sweating all over body) and ASTHENIA (Weak). On 07-Feb-2021, PAIN (Felt like a truck ran over her), MYALGIA (Was very sore and achy all over), HOT FLUSH (Severe hot flashes) and HYPERHIDROSIS (sweating all over body) had resolved and ASTHENIA (Weak) was resolving. Not Provided          treatment to the events not provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-008873.   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: additional information received patient demographic details, patient historical condition,  concomitant medications, outcome if the events are updated from recovering to recovered .
Fever to 103.3F, body aches, malaise, nausea, intermittent headaches, chills, mild cough, diarrhea.
psychiatric issue; This is a spontaneous report from a contactable consumer reported for his son. A 39-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 11Mar2021 at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. The patient was unable to receive the second dose as of today 01Apr2021.  He was currently inpatient in the behavior health unit for an unrelated psychiatric issue.  Father and psychiatrist wanted him to receive the second dose of the vaccine, but the hospital was unwilling to administer the vaccine.   He was going to be transferred to hospital in another state and the hospital there said they wanted him to get vaccinated before he arrived. Father stated psychiatric issue was unrelated. The outcome of the event was unknown.  Information of Lot /batch number are requested.; Sender's Comments: The event of psychiatric issue was considered as an intercurrent condition and unrelated to the use of BNT162B2.